v3.25.4
EQUITY (Tables)
6 Months Ended
Dec. 31, 2025
Equity [Abstract]  
SCHEDULE OF WARRANTS OUTSTANDING

The remaining outstanding warrants as of December 31, 2025 are:

    

   Warrants Outstanding   Exercise Price   Expiration Date
            
July 2021 IPO   87,500   $7.00   June 2026
November 2021 SPA   481,000   $1.75   November 2026
November 2021 SPA   169,000   $1.75   May 2027
Total   737,500         

SCHEDULE OF STOCK OPTION FAIR VALUE ASSUMPTION

Stock options have been recorded at their fair value. The Black-Scholes option-pricing model assumptions used to value the issuance of stock options under the Plan for the specific periods below are noted in the following table:

    

             
   For the Three Months Ended
December 31,
   For the Six Months Ended
December 31,
 
   2025   2024   2025   2024 
Weighted average expected terms (in years)   5.5    6.0    5.8    6.0 
Weighted average expected volatility   120.3%   81.5%   125.3%   87.4%
Weighted average risk-free interest rate   3.9%   3.6%   4.0%   3.8%
Expected dividend yield   0.0%   0.0%   0.0%   0.0%
SUMMARY OF STOCK OPTION ACTIVITY

The following is a summary of the Company’s stock option activity for the six months ended December 31, 2025 and 2024, excluding the executive Target Options:

     

       Weighted Average     
           Remaining     
       Exercise   Contractual   Intrinsic 
   Options   Price   Term (Yrs)   Value 
Outstanding as of July 1, 2025   2,766,206   $3.37    5.6   $- 
Options granted   216,000    2.13    9.7    - 
Options exercised   -    -    0.0    - 
Options forfeited / cancelled   (148,385)   3.08    7.5    - 
Outstanding as of December 31, 2025   2,833,821   $3.30    5.3   $- 
Exercisable as of December 31, 2025   2,001,866   $3.45    4.5   $- 

 
       Weighted Average     
           Remaining     
       Exercise   Contractual   Intrinsic 
   Options   Price   Term (Yrs)   Value 
Outstanding as of July 1, 2024   3,643,880   $3.95    6.5   $- 
Options granted   196,301    2.50    9.6    - 
Options exercised   (35,600)   2.50    2.3    - 
Options forfeited / cancelled   (760,304)   4.54    7.5    2,886 
Outstanding as of December 31, 2024   3,044,277   $3.73    5.9   $528,944 
Exercisable as of December 31, 2024   1,751,773   $3.93    4.6   $252,829 

 
SCHEDULE OF STOCK OPTION BASED EXPENSE

The Company’s stock option-based expense for the three months ended December 31, 2025 and 2024 consisted of the following:

     

             
   For the Three Months Ended   For the Six Months Ended 
   December 31,   December 31, 
   2025   2024   2025   2024 
Stock option-based expense :                    
Research and development expenses  $48,584   $(17,580)  $83,696   $121,610 
General and administrative expenses   137,734    108,835    222,417    221,843 
Sales and marketing expenses   20,873    (27,533)   34,213    66,535 
Board option expense   102,235    12,459    204,470    24,919 
Total  $309,426   $76,181   $544,796   $434,907